All In Biotech

Investigational drug · Phase 2

Benmelstobart

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alveolar Soft Part Sarcoma, Non-Small Cell Lung Cancer, Gastroesophageal Adenocarcinoma.

Phase 2

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

4

4 still active

All registered trials

44

Any phase or sponsor naming "Benmelstobart"

First trial start

2023

Jul 27, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Benmelstobart", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Alveolar Soft Part Sarcoma
  • Non-Small Cell Lung Cancer
  • Gastroesophageal Adenocarcinoma
  • Malignant Neoplasms of Digestive Organs

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Stomach and esophageal cancer · Sarcoma · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Benmelstobart" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 39 on PubMed

Also in development for Alveolar Soft Part Sarcoma

  • Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.